JNJ

187.99

-0.51%↓

ABT

123.06

-1.43%↓

TMO

565.36

+0.36%↑

ISRG

531.99

-0.02%↓

DHR

215.72

-0.76%↓

JNJ

187.99

-0.51%↓

ABT

123.06

-1.43%↓

TMO

565.36

+0.36%↑

ISRG

531.99

-0.02%↓

DHR

215.72

-0.76%↓

JNJ

187.99

-0.51%↓

ABT

123.06

-1.43%↓

TMO

565.36

+0.36%↑

ISRG

531.99

-0.02%↓

DHR

215.72

-0.76%↓

JNJ

187.99

-0.51%↓

ABT

123.06

-1.43%↓

TMO

565.36

+0.36%↑

ISRG

531.99

-0.02%↓

DHR

215.72

-0.76%↓

JNJ

187.99

-0.51%↓

ABT

123.06

-1.43%↓

TMO

565.36

+0.36%↑

ISRG

531.99

-0.02%↓

DHR

215.72

-0.76%↓

Search

Ionis Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

75 2.29

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

73.27

Max

75.37

Pagrindiniai rodikliai

By Trading Economics

Pajamos

270M

124M

Pardavimai

320M

452M

Pelno marža

27.331

Darbuotojai

1,069

EBITDA

294M

150M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+12.41% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.1B

12B

Ankstesnė atidarymo kaina

72.71

Ankstesnė uždarymo kaina

75

Naujienos nuotaikos

By Acuity

50%

50%

168 / 373 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-30 23:32; UTC

Karštos akcijos

Stocks to Watch: Amazon, Reddit, SPS Commerce

2025-10-30 23:02; UTC

Uždarbis

AIA Group 3Q Value of New Business Grew

2025-10-30 23:45; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

2025-10-30 23:00; UTC

Uždarbis

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

2025-10-30 22:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2025-10-30 22:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

2025-10-30 22:56; UTC

Rinkos pokalbiai

Australia Shares Shaping to Pare Recent Losses -- Market Talk

2025-10-30 22:35; UTC

Uždarbis

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

2025-10-30 22:35; UTC

Uždarbis

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

2025-10-30 22:31; UTC

Uždarbis

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

2025-10-30 22:29; UTC

Uždarbis

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

2025-10-30 22:27; UTC

Uždarbis

Minas Buenaventura 3Q EPS 66c >BVN

2025-10-30 22:27; UTC

Uždarbis

Minas Buenaventura 3Q Rev $431M >BVN

2025-10-30 22:27; UTC

Uždarbis

Minas Buenaventura 3Q Net $179M >BVN

2025-10-30 22:16; UTC

Rinkos pokalbiai
Uždarbis

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

2025-10-30 22:14; UTC

Uždarbis

Review & Preview: A Tech Earnings Storm -- Barrons.com

2025-10-30 22:00; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

2025-10-30 21:39; UTC

Uždarbis

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

2025-10-30 21:26; UTC

Uždarbis

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

2025-10-30 21:14; UTC

Rinkos pokalbiai
Uždarbis

Apple Sees Record Quarterly Services Revenue -- Market Talk

2025-10-30 21:09; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-10-30 21:09; UTC

Rinkos pokalbiai
Uždarbis

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

2025-10-30 21:04; UTC

Uždarbis

Apple Expects Big December Quarter on iPhone Upgrades -- Update

2025-10-30 21:03; UTC

Uždarbis

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

2025-10-30 21:03; UTC

Uždarbis

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

2025-10-30 21:00; UTC

Uždarbis

Eldorado Gold Skouries on Track for 1Q of 2026

2025-10-30 21:00; UTC

Uždarbis

Eldorado Gold 3Q Adj EPS 41c >EGO

2025-10-30 21:00; UTC

Uždarbis

Eldorado Gold 3Q Rev $434.7M >EGO

2025-10-30 21:00; UTC

Uždarbis

Eldorado Gold 3Q Net $56M >EGO

2025-10-30 21:00; UTC

Uždarbis

Eldorado Gold 3Q EPS 27c >EGO

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

12.41% į viršų

12 mėnesių prognozė

Vidutinis 80.8 USD  12.41%

Aukščiausias 100 USD

Žemiausias 46 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

21 ratings

17

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

168 / 373 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat